Sector News

Boston Scientific to buy Endo’s urology portfolio for $1.65 billion

March 2, 2015
Life sciences
(Reuters) – Medical device maker Boston Scientific Corp (BSX.N) said it will buy Endo International Plc’s (ENDP.O) American Medical Systems’ men’s and prostate health business for up to $1.65 billion.
 
The purchase ends a nearly decade-long deal drought for Boston Scientific, which has not completed a large takeover since its 2006 acquisition of heart device maker Guidant Corp for $27 billion.
 
The deal value includes additional $50 million in milestone based on 2016 sales, Boston Scientific said on Monday.
 
AMS’ men’s and prostate health businesses, which generated 2014 sales of about $400 million, provides treatments for conditions such as erectile dysfunction, enlarged prostate and bladder leakage.
 
Reuters reported last week that Boston Scientific was close to buying Endo’s AMS medical device unit.
 
Monday’s deal, which is expected to close in the third quarter of 2015, does not include AMS’ women’s health business.
 
Endo said in a separate statement it is evaluating strategic alternatives for the business.
 
Boston Scientific said it will finance the deal through a combination of existing and newly committed credit facilities.
 
BofA Merrill Lynch is Endo’s financial adviser and Skadden Arps Slate Meagher & Flom LLP the legal adviser.
 
J.P. Morgan Securities is financial adviser to Boston Scientific.
 
(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D’Souza)

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach